Sunitinib Teva

Package Leaflet: Information for the User

Sunitinib Teva, 12.5 mg, hard capsules

Sunitinib Teva, 25 mg, hard capsules Sunitinib Teva, 37.5 mg, hard capsules

Sunitinib Teva, 50 mg, hard capsules

Sunitinib

Read all of this leaflet carefully before taking this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack and other information

• 1. What Sunitinib Teva is and what it is used for
• 2. Before you take Sunitinib Teva
• 3. How to take Sunitinib Teva
• 4. Possible side effects
• 5. How to store Sunitinib Teva
• 6. Contents of the pack and other information

1. What Sunitinib Teva is and what it is used for

Sunitinib Teva contains the active substance sunitinib, which is a protein kinase inhibitor.
Sunitinib Teva is used to treat cancer. It works by inhibiting the activity of certain proteins involved in the growth and spread of cancer cells.
Sunitinib Teva is used to treat the following types of cancer in adults:

• gastrointestinal stromal tumour (GIST), a type of stomach and intestine cancer, when imatinib (another cancer medicine) is no longer effective or cannot be taken;
• metastatic renal cell carcinoma (MRCC), a type of kidney cancer that has spread to other parts of the body;
• pancreatic neuroendocrine tumours (pNET), tumours that arise from hormone-producing cells in the pancreas, which are progressing and cannot be surgically removed.

If you have any questions about how Sunitinib Teva works or why it has been prescribed for you, ask your doctor.

2. Before you take Sunitinib Teva

When not to take Sunitinib Teva

• If you are allergic to sunitinib or any of the other ingredients of this medicine (listed in section 6).

(see section 6).

Warnings and precautions

Before taking Sunitinib Teva, tell your doctor:

• If you have high blood pressure. Sunitinib Teva may increase your blood pressure. Your doctor may check your blood pressure during treatment with Sunitinib Teva, and you may need to take medicines to lower your blood pressure.
• If you have or have had bleeding or blood disorders. Treatment with Sunitinib Teva may increase the risk of bleeding or changes in the number of certain blood cells, which can cause anaemia or affect blood clotting. If you are taking warfarin or acenocoumarol, blood-thinning medicines used to prevent blood clots, there may be a higher risk of bleeding. Tell your doctor about any bleeding during treatment with Sunitinib Teva.
• If you have heart problems. Sunitinib Teva may cause heart problems. Tell your doctor if you feel very tired, have shortness of breath, or swelling of your feet or ankles.
• If you have irregular heart rhythms. Sunitinib Teva may cause irregular heart rhythms. During treatment with Sunitinib Teva, your doctor may perform an electrocardiogram to check for these problems. Tell your doctor if you experience dizziness, fainting, or irregular heart rhythms during treatment with Sunitinib Teva.
• If you have recently had blood clots in your veins or arteries (including stroke, heart attack, embolism, or thrombosis). You should immediatelycontact your doctor if you experience symptoms such as chest pain or tightness, arm, back, neck, or jaw pain, shortness of breath, numbness or weakness on one side of the body, difficulty speaking, or headache or dizziness.
• If you have or have had an aneurysm (enlargement and weakening of the wall of a blood vessel) or a tear in the wall of a blood vessel.
• If you have or have had damage to the smallest blood vessels, called microangiopathic haemolytic anaemia. Tell your doctor if you experience fever, fatigue, tiredness, bruising, bleeding, swelling, confusion, loss of vision, or seizures.
• If you have thyroid problems. Sunitinib Teva may cause thyroid problems. Tell your doctor if you feel very tired, feel cold, or have a hoarse voice during treatment with Sunitinib Teva. Your doctor should check your thyroid function before starting treatment with Sunitinib Teva and regularly during treatment. If your thyroid is not producing enough thyroid hormone, you may need to take thyroid hormone replacement.
• If you have or have had pancreas or gallbladder problems. Tell your doctor if you experience any of the following symptoms: stomach pain (upper abdomen), nausea, vomiting, and fever. These may be symptoms of pancreatitis or gallbladder inflammation.
• If you have or have had liver problems. Tell your doctor if you experience any of the following symptoms of liver problems: itching, yellowing of the eyes or skin, dark urine, or pain or discomfort in the right upper abdomen. Your doctor should perform blood tests to check your liver function before starting treatment with Sunitinib Teva, during treatment, and if you experience any symptoms.
• If you have or have had kidney problems. Your doctor will monitor your kidney function.
• If you are going to have surgery or have recently had surgery. Sunitinib Teva may affect wound healing. The medicine is usually stopped in patients before surgery. Your doctor will decide when to restart Sunitinib Teva.
• A dental examination is recommended before starting treatment with Sunitinib Teva.
• If you experience mouth pain, toothache, and/or jaw pain, swelling or ulceration of the mouth, numbness or heaviness of the jaw, or tooth mobility, you should immediatelyinform your oncologist and dentist;
• If you need invasive dental procedures or surgery, you should inform your dentist about your treatment with Sunitinib Teva, especially if you are also taking or have taken intravenous bisphosphonates. Bisphosphonates are medicines used to prevent bone disorders, which may be taken for another condition.
• If you have or have had skin and subcutaneous tissue disorders. During treatment with this medicine, you may experience a painful skin ulcer (pyoderma gangrenosum) or a life-threatening infection of the skin and soft tissues (necrotising fasciitis). You should immediatelycontact your doctor if you experience symptoms of infection around a skin wound, including fever, pain, redness, swelling, or discharge of pus or blood. These disorders usually resolve after stopping treatment.
• If you have or have had seizures. Tell your doctor as soon as possible if you experience high blood pressure, headache, or vision loss.
• If you have diabetes. In patients with diabetes, blood sugar levels should be regularly checked to assess whether the dose of the anti-diabetic medicine needs to be adjusted to minimise the risk of low blood sugar. Tell your doctor as soon as possible if you experience symptoms of low blood sugar (tiredness, palpitations, sweating, hunger, and loss of consciousness).

Children and adolescents

Sunitinib Teva is not recommended for patients under 18 years of age.

Sunitinib Teva and other medicines

Tell your doctor or pharmacist about all medicines you are taking or have recently taken, including those obtained without a prescription and those you plan to take.
Some medicines may affect the levels of Sunitinib Teva in your body. Tell your doctor if you are taking medicines containing the following active substances:

• ketokonazole, itraconazole - used to treat fungal infections;
• erythromycin, clarithromycin, rifampicin - used to treat infections;
• ritonavir - used to treat HIV infections;
• dexamethasone - a corticosteroid used in various diseases (such as allergic disorders and/or respiratory disorders or skin diseases);
• phenytoin, carbamazepine, phenobarbital - used to treat epilepsy and other neurological conditions;
• herbal preparations containing St. John's Wort (Hypericum perforatum) - used to treat depression and anxiety disorders.

Sunitinib Teva with food and drink

Do not drink grapefruit juice while taking Sunitinib Teva.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Women who may become pregnant should use effective contraception during treatment with Sunitinib Teva.
Women who are breast-feeding should inform their doctor. Do not breast-feed while taking Sunitinib Teva.

Driving and using machines

If you experience dizziness or extreme tiredness, be careful when driving or using machines.

Sunitinib Teva contains sodium

This medicine contains less than 1 mmol (23 mg) of sodium per hard capsule, which is essentially 'sodium-free'.

3. How to take Sunitinib Teva

Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor.
Your doctor will prescribe the dose that is right for you, depending on the type of cancer you have. For patients being treated for:

• GIST or MRCC, the usual dose is 50 mg taken once a day for 28 days (4 weeks), followed by a 14-day (2-week) break (without treatment), in 6-week treatment cycles.
• pNET, the usual dose is 37.5 mg taken once a day continuously.

Your doctor will determine the right dose for you and when to stop treatment with Sunitinib Teva.
Sunitinib Teva can be taken with or without food.

If you take more Sunitinib Teva than you should

If you take too many capsules, contact your doctor immediately.
Medical attention may be necessary.

If you forget to take Sunitinib Teva

Do not take a double dose to make up for a forgotten dose.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
Immediatelycontact your doctor if you experience any of the following serious side effects (see also section 2 Before you take Sunitinib Teva):
Heart problems. Tell your doctor if you feel very tired, have shortness of breath, or swelling of your feet and ankles. These may be symptoms of heart problems, including heart failure and heart muscle problems (cardiomyopathy).
Lung or breathing problems. Tell your doctor if you experience coughing, chest pain, sudden shortness of breath, or coughing up blood. These may be symptoms of a condition called pulmonary embolism, where blood clots travel to the lungs.
Kidney problems. Tell your doctor if you experience changes in urination or lack of urination, which may be symptoms of kidney failure.
Bleeding. Tell your doctor if you experience any of the following symptoms or severe bleeding during treatment with Sunitinib Teva: stomach pain or swelling; vomiting blood; black or tarry stools; blood in urine; headache or changes in consciousness; coughing up blood or bloody sputum from the lungs or airways.
Tumour rupture leading to intestinal perforation. Tell your doctor if you experience severe stomach pain, fever, nausea, vomiting, blood in stool, or changes in bowel movements.
Other side effects of Sunitinib Teva may include:

• Very common: may affect more than 1 in 10 people
• decreased number of platelets, red blood cells, and/or white blood cells (e.g. neutrophils)
• shortness of breath
• high blood pressure
• extreme tiredness, loss of strength
• swelling caused by fluid accumulation under the skin and around the eyes, allergic rash, deep rash
• mouth pain and/or irritation, painful mouth ulcers, and/or inflammation, and/or dryness of the mouth, taste disturbances, stomach upset, nausea, vomiting, diarrhoea, constipation, abdominal pain or swelling, loss of or decreased appetite
• decreased thyroid activity (hypothyroidism)
• dizziness
• headache
• nosebleeds
• back pain, joint pain
• arm and leg pain
• discoloration of the skin and/or colour changes, excessive skin pigmentation, hair colour changes, hand-foot syndrome, rash, dry skin
• cough
• fever
• difficulty sleeping

Common: may affect up to 1 in 10 people

• blood clots in blood vessels
• insufficient blood supply to the heart due to a blockage or narrowing of the coronary arteries
• chest pain
• decreased amount of blood pumped by the heart
• fluid accumulation, including in the lungs
• infections
• complication after a severe infection (sepsis), which can cause tissue damage, organ failure, and death
• low blood sugar levels (see section 2)
• protein loss in urine, sometimes causing swelling
• flu-like syndrome
• abnormal blood test results, including pancreas and liver enzymes
• high levels of uric acid in the blood
• haemorrhoids, anal pain, gum bleeding, difficulty swallowing or loss of swallowing ability
• burning or painful sensation of the tongue, inflammation of the mucous membranes, excessive gas in the stomach or intestines
• weight loss
• musculoskeletal pain (muscle and bone pain), muscle weakness, muscle fatigue, muscle spasms
• dryness of the nasal mucosa, feeling of nasal congestion
• excessive tearing
• skin sensitivity disturbances, itching, skin peeling, and/or inflammation, blisters, acne, nail discolouration, hair loss
• skin sensation disturbances
• sensitivity disturbances, especially to touch
• heartburn
• dehydration
• hot flushes
• abnormal urine colour
• depression
• chills

Uncommon: may affect up to 1 in 100 people

• life-threatening infection of the skin and soft tissues (necrotising fasciitis) (see section 2)
• stroke
• heart attack due to interruption or narrowing of blood flow to the heart
• changes in heart rhythm or electrical activity
• fluid accumulation around the heart (pericardial effusion)
• liver failure
• stomach pain due to pancreatitis
• tumour rupture leading to intestinal perforation
• inflammation of the gallbladder (with or without gallstones)
• formation of abnormal connections between one body cavity and another or with the skin
• mouth pain, toothache, and/or jaw pain, swelling or ulceration of the mouth, numbness or heaviness of the jaw, or tooth mobility. These may be symptoms of jawbone damage (osteonecrosis), see section 2
• excessive production of thyroid hormones leading to increased resting metabolism
• abnormal wound healing after surgery
• increased activity of a muscle enzyme (creatine phosphokinase) in the blood
• excessive allergic reaction, including fever, skin rash, itching, hives, swelling of any part of the body, and difficulty breathing
• inflammation of the large intestine (colitis, ischaemic colitis)

Rare: may affect up to 1 in 1,000 people

• severe skin and/or mucous membrane reaction (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme)
• life-threatening tumour lysis syndrome, which is a group of metabolic complications that can occur during cancer treatment. These complications are caused by the breakdown products of dying cancer cells and can include nausea, shortness of breath, irregular heartbeat, muscle cramps, seizures, kidney changes, and fatigue associated with abnormal laboratory test results (high levels of potassium, uric acid, and phosphorus, and low levels of calcium in the blood), which can lead to kidney damage and acute kidney failure.
• abnormal muscle breakdown, which can cause kidney disease (rhabdomyolysis)
• abnormal brain changes, which can cause a syndrome of symptoms including headache, confusion, seizures, and vision loss (reversible posterior leukoencephalopathy syndrome)
• painful skin ulcer (pyoderma gangrenosum)
• liver inflammation
• thyroid gland inflammation
• damage to the smallest blood vessels, called microangiopathic haemolytic anaemia

Frequency not known (frequency cannot be estimated from the available data)

• enlargement and weakening of the wall of a blood vessel or tear in the wall of a blood vessel (aneurysm and arterial dissection).
• lack of energy, confusion, drowsiness, loss of consciousness, or coma - these symptoms may be signs of a toxic effect of high ammonia levels in the blood on the brain (hyperammonaemic encephalopathy).

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. Side effects can be reported to the national reporting system listed below.
You can also report side effects directly via the contact details below.
In the UK, you can report side effects to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card Scheme: www.mhra.gov.uk/yellowcard.
In Ireland, you can report side effects to the Health Products Regulatory Authority (HPRA) using the online reporting form: www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects.
By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Sunitinib Teva

• Keep this medicine out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the carton, bottle, and blister after EXP. The expiry date refers to the last day of that month.

Do not store above 30°C. Store in the original package to protect from moisture.

• Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What Sunitinib Teva contains

The active substance is sunitinib. Each hard capsule contains 12.5 mg of sunitinib.
The other ingredients are:

Capsule content:mannitol, povidone (K-25), croscarmellose sodium, magnesium stearate.
Capsule shell:gelatin, titanium dioxide (E 171), iron oxide red (E 172), and iron oxide yellow (E 172).
Printing ink:shellac, iron oxide black (E 172), propylene glycol, concentrated ammonia solution, and potassium hydroxide.

Sunitinib Teva, 25 mg, hard capsules

The active substance is sunitinib. Each hard capsule contains 25 mg of sunitinib.
The other ingredients are:

Capsule content:mannitol, povidone (K-25), croscarmellose sodium, magnesium stearate.
Capsule shell:gelatin, titanium dioxide (E 171), iron oxide red (E 172), and iron oxide yellow (E 172).
Printing ink:shellac, iron oxide black (E 172), propylene glycol, concentrated ammonia solution, and potassium hydroxide.

Sunitinib Teva, 37.5 mg, hard capsules

The active substance is sunitinib. Each hard capsule contains 37.5 mg of sunitinib.
The other ingredients are:

Capsule content:mannitol, povidone (K-25), croscarmellose sodium, magnesium stearate.
Capsule shell:gelatin, titanium dioxide (E 171), and iron oxide yellow (E 172).
Printing ink:shellac, iron oxide black (E 172), propylene glycol, concentrated ammonia solution, and potassium hydroxide.

Sunitinib Teva, 50 mg, hard capsules

The active substance is sunitinib. Each hard capsule contains 50 mg of sunitinib.
The other ingredients are:

Capsule content:mannitol, povidone (K-25), croscarmellose sodium, magnesium stearate.
Capsule shell:gelatin, titanium dioxide (E 171), iron oxide red (E 172), and iron oxide yellow (E 172).
Printing ink:shellac, iron oxide black (E 172), propylene glycol, concentrated ammonia solution, and potassium hydroxide.

What Sunitinib Teva looks like and contents of the pack

Sunitinib Teva, 12.5 mg, hard capsules
Orange hard gelatin capsules with an orange cap and body, with black printing "12.5" on the cap. Each capsule, size 4 (approximately 14.2 mm in length), contains orange granules.
Sunitinib Teva, 25 mg, hard capsules
Light orange hard gelatin capsules with a light orange cap and body, with black printing "25" on the cap. Each capsule, size 3 (approximately 15.8 mm in length), contains orange granules.
Sunitinib Teva, 37.5 mg, hard capsules
Yellow hard gelatin capsules with a yellow cap and body, with black printing "37.5" on the cap. Each capsule, size 2 (approximately 17.6 mm in length), contains orange granules.
Sunitinib Teva, 50 mg, hard capsules
Light orange hard gelatin capsules with a light orange cap and body, with black printing "50" on the cap. Each capsule, size 2 (approximately 17.6 mm in length), contains orange granules.
Sunitinib Teva is available in white high-density polyethylene (HDPE) bottles containing 30 capsules, in blisters containing 28 or 30 capsules, and in blister packs containing 28x1 or 30x1 capsules.
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Teva B.V.
Swensweg 5
2031 GA Haarlem
Netherlands

Manufacturer/Importer:

Teva Operations Poland Sp. z o.o.
ul. Mogilska 80
31-546 Kraków
Poland
Merckle GmbH
Ludwig-Merckle-Strasse 3
89143 Blaubeuren
Germany
PLIVA Hrvatska d.o.o. (PLIVA Croatia Ltd.)
Prilaz baruna Filipovića 25
Zagreb 10000
Croatia
Actavis International Ltd.
4 Sqaq tal-Gidi off Valletta Road,
Luqa LQA 6000,
Malta
Balkanpharma-Dupnitsa AD
3 Samokovsko Shosse Str., Dupnitsa, 2600
Bulgaria

For further information on this medicine, contact the Marketing Authorisation Holder:

Teva Pharmaceuticals Polska Sp. z o.o.
ul. Emilii Plater 53
00-113 Warszawa
tel.: (22) 345 93 00

Date of last revision of the leaflet: May 2024